Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Sees Significant Drop in Short Interest

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the target of a significant decrease in short interest during the month of February. As of February 28th, there was short interest totalling 36,100 shares, a decrease of 23.2% from the February 13th total of 47,000 shares. Based on an average daily trading volume, of 830,300 shares, the short-interest ratio is presently 0.0 days. Approximately 0.1% of the shares of the company are sold short.

Biodexa Pharmaceuticals Stock Performance

NASDAQ BDRX opened at $2.02 on Wednesday. Biodexa Pharmaceuticals has a 52-week low of $1.84 and a 52-week high of $74.00. The business’s 50-day moving average is $3.81.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.